Loading...
Market
Primary reason for Trodelvy withdrawal in urothelial cancer?
2
Resolution / Starting Odds
Lack of efficacy • 25%
Safety concerns • 25%
Strategic business decision • 25%
Regulatory challenges • 25%
Official statements or press releases from Gilead Sciences
Story
Gilead to Withdraw US Approval for Trodelvy in Urothelial Cancer on Friday
Oct 18, 2024, 01:00 PM
Gilead Sciences has announced its decision to voluntarily withdraw the U.S. accelerated approval for Trodelvy (sacituzumab govitecan-hziy) for the treatment of adults with locally advanced or metastatic urothelial cancer. This decision, announced on Friday, follows consultations with the FDA and the results from the TROPiCS-04 study, which did not meet the overall survival endpoint. The withdrawal specifically affects patients who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. Other indications for Trodelvy remain unaffected. The drug was used in previously treated bladder cancer patients.
View original story
Similar markets
Approval for a new indication • 25%
Rejection of a new application • 25%
Withdrawal of another indication • 25%
No major action • 25%
Full Approval • 25%
Accelerated Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Yes • 50%
No • 50%
Significant Improvement • 25%
Moderate Improvement • 25%
No Change • 25%
Worse Outcomes • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%